RTGN · XBRL financial data
RetinalGenix Technologies financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (RTGN's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Research and development | 680 | — | 524 | 373 | 83 |
| General and administrative | 1,188 | 807 | 899 | 1,334 | 1,301 |
| Total operating expenses | 2,177 | 3,909 | 2,087 | 4,317 | 2,425 |
| Interest expense | 3 | 5 | 4 | 4 | 4 |
| Net income (loss) | (2,179) | (3,914) | (2,091) | (4,321) | (2,429) |
| Earnings per share, basic USD per share | (0.05) | (0.25) | (0.12) | (0.24) | (0.13) |
| Earnings per share, diluted USD per share | — | (0.25) | (0.12) | (0.24) | (0.13) |
| Weighted average shares, basic thousands of shares | 41,247 | 15,584 | 17,352 | 17,941 | 18,563 |
| Weighted average shares, diluted thousands of shares | — | 15,584 | 17,352 | 17,941 | 18,563 |
Balance sheet
CSVFiscal years (RTGN's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 5 | 0 | 0 | 6 | 15 |
| Total current assets | 5 | 0 | 0 | 6 | 15 |
| Property and equipment, net | — | 0 | 0 | 0 | — |
| Right-of-use asset | — | — | — | 7 | 4 |
| Total assets | 5 | 0 | 0 | 15 | 21 |
| Accounts payable | 251 | — | — | — | — |
| Total current liabilities | — | — | 1,406 | 1,471 | 2,320 |
| Lease liability, non-current | — | — | — | 7 | 4 |
| Total liabilities | 470 | 1,069 | 1,406 | 1,478 | 2,324 |
| Accumulated deficit | (5,104) | (9,018) | (11,109) | (15,430) | (17,859) |
| Total stockholders' equity | (465) | (1,069) | (1,406) | (1,463) | (2,303) |
| Total liabilities and equity | 5 | 0 | 0 | 15 | 21 |
| Common shares outstanding (cover page) thousands of shares | 14,282 | 17,272 | 17,785 | 18,522 | 18,755 |
Cash flows
CSVFiscal years (RTGN's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Net income (loss) | (2,179) | (3,914) | (2,091) | (4,321) | (2,429) |
| Stock-based compensation | 308 | 259 | 664 | 2,610 | 1,041 |
| Net cash from operating activities | (1,167) | (199) | (348) | (742) | (558) |
| Proceeds from issuing common stock | 1,083 | 61 | — | 503 | 398 |
| Net cash from financing activities | 1,170 | 195 | 348 | 748 | 567 |
| Net change in cash | 3 | (5) | (0) | 6 | 9 |
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| RetinalGenix Technologies | 27 | not reported | (137)* | 18.8M | 0.2 quarters | 10-QJun 30, 2026 |
| Beyond Air | 5,509 | 1,768 | (4,946) | 957,631 | 2.0 quarters | 10-QJun 30, 2026 |
| Harvard Apparatus Regenerative Technology | 351 | 414 | (569)* | 17.6M | 0.6 quarters | 10-QJun 30, 2026 |
| Nexalin Technology | 1,005 | 12 | (1,802)* | 22.0M | 0.6 quarters | 10-QJun 30, 2026 |
| Iridex | 4,680 | 12,566 | 174* | 17.6M | — | 10-QJul 4, 2026 |
| Biotricity | 467 | 4,277 | 507 | 19.9M | — | 10-QJun 30, 2026 |
| VASO | 38,291 | not reported | 17,444* | 176.0M | — | 10-QJun 30, 2026 |
| Envoy Medical | 19,679 | 51 | (5,456)* | 77.2M | 3.6 quarters | 10-QJun 30, 2026 |
| Dror Ortho-Design | 94 | not reported | (305)* | 977.0M | 0.3 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.